NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report released on Monday,Benzinga reports. D. Boral Capital currently has a $34.00 target price on the stock.

Several other equities analysts have also commented on the company. Zacks Research raised NRx Pharmaceuticals to a “hold” rating in a research note on Wednesday, September 10th. BTIG Research restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. Ascendiant Capital Markets increased their target price on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday, October 16th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.75.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP opened at $2.64 on Monday. The company’s 50-day moving average is $3.02 and its two-hundred day moving average is $2.87. NRx Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $6.01. The firm has a market capitalization of $52.30 million, a price-to-earnings ratio of -1.18 and a beta of 1.76.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.67). As a group, equities analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of NRXP. Anson Funds Management LP lifted its position in shares of NRx Pharmaceuticals by 535.1% during the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after purchasing an additional 993,401 shares in the last quarter. Geode Capital Management LLC increased its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares during the period. Ethos Financial Group LLC purchased a new stake in NRx Pharmaceuticals during the 3rd quarter worth approximately $39,000. One Wealth Management Investment & Advisory Services LLC lifted its holdings in NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares in the last quarter. Finally, AdvisorShares Investments LLC boosted its position in NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares during the period. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.